NCT04425460Unknown3 期
A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase III Clinical Study Evaluating the Efficacy and Safety of Favipiravir in the Treatment of Adult Patients With COVID-19-Moderate Type
Zhejiang Hisun Pharmaceutical Co. Ltd.9 个研究点 分布在 3 个国家目标入组 256 人开始时间: 2020年6月最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 256
- 试验地点
- 9
- 主要终点
- Time from randomization to clinical recovery
研究概览
简要总结
This is a multi-center, randomized, double-blind, placebo-controlled, phase III clinical study to evaluate the efficacy of Favipiravir combined with supportive care for adult patients with COVID-19-Moderate type.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Voluntarily participating in the clinical study; fully understanding and being fully informed of the study and having signed the Informed Consent Form (ICF); willingness and capability to complete all the study procedures;
- •Age 18-75 years (inclusive) at the time of signing ICF;
- •Being confirmed with COVID-19-Moderate type according to Competent Authority and Ministry of Health and respective country guidelines and recommendations reported in Appendix 1 (a, b, c, d) to the present protocol. Based on comprehensive analysis and judgement taking into account both the epidemiological history and clinical manifestations, the diagnosis is to be confirmed for suspected cases or suspected cases/clinically diagnosed cases with all of the following etiological evidences:
- •Positivity in RT-PCR 2019-nCov test on respiratory tract specimens;
- •High homology with known gene sequence of 2019-nCov in viral gene sequencing on respiratory tract specimens.
- •Chest imaging (CT as first option or X-ray if CT not possible)-documented pneumonia; if CT cannot be performed, Pneumonia confirmed by X-ray may be used. The method of chest imaging pneumonia diagnosis must be consistent all through the study period;
- •Patients with pyrexia (axillary ≥37℃ or oral ≥ 37.5℃, or tympanic or rectal≥38℃) or either respiratory rate >24/min and <30/min or cough; For not hospitalized patients, the Investigator should maintain the detection method consistent through study period. In addition, the Investigator should maintain the data collection and quality compliant with GCP requirements.
- •The interval between symptoms onset and randomization is no more than 10 days; symptoms onset is primarily based on pyrexia, and can be based on cough or other related symptoms for patients without experiencing pyrexia following onset (it is strongly recommended that the interval between symptoms onset and randomization should not exceed 5 days);
- •For female subjects: evidence of post-menopause, or, for pre-menopause subjects, negative pre-treatment serum or urine pregnancy test. Menopause is defined as amenorrhea for at least 12 months without other medical cause, with the following age-specific requirements:
- •For female subjects aged <50 years: menopause for at least 12 months following withdrawal of exogenous hormonal therapy, with LH or FSH within the post-menopausal ranges, or having undergone any contraceptive surgery (bilateral oophorectomy or hysterectomy);
- •For female subjects aged ≥ 50 years: menopause for at least 12 months following withdrawal of exogenous hormonal therapy, or having undergone radiotherapy-induced oophorectomy with amenorrhea >1 year, or having undergone chemotherapy-induced menopause with amenorrhea>1 year, or having undergone any contraceptive surgery (bilateral oophorectomy or hysterectomy).
- •Eligible subjects of child-bearing age (male or female) must agree to take effective contraceptive measures (including hormonal contraception, barrier methods or abstinence) with his/her partner during the study period and for at least 3 months (in male) and 1 month (in female)following the last study treatment; in addition:
- •For female participants of childbearing potential only highly effective methods (failure rate < 1 %) plus one barrier method is allowed throughout the period of relevant systemic exposure with Favipiravir. Double barrier methods alone are not considered as highly effective. Additionally, pregnancy testing at baseline only is not deemed sufficient and must be repeated more frequently, at least if clinical signs of pregnancy occur and at follow-up / end of study.
- •male participants, if vasectomized or not, must wear a condom each time having heterosexual intercourse throughout the period of relevant systemic exposure with Favipiravir (as it is distributed to seminal fluid).
- •male participant must be instructed not to have intercourse with pregnant women throughout the period of relevant systemic exposure with Favipiravir.
- •For further details on contraception in clinical trials, please refer to the CTFG guidance: https://www.hma.eu/fileadmin/dateien/Human_Medicines/01- About_HMA/Working_Groups/CTFG/2014_09_HM A_CTFG_Contraception.pd
- •Not participating in any other drug clinical studies before completion of the present study.
排除标准
- •Where, in the opinion of the investigator, participation in this study will not be in the best interest of the subject, or any other circumstances that prevent the subject from participating in the study safely;
- •Refractory nausea, vomiting, or chronic gastrointestinal disorders, inability to swallow the study drug or having undergone extensive bowel resection which may affect adequate absorption of Favipiravir;
- •Severe liver disease: underlying liver cirrhosis or alanine aminotransferase (ALT)/aspartate aminotransferase (AST) elevated over 5 times the ULN;
- •Gout/history of gout or hyperuricemia (above the ULN);
- •Oxygen saturation (SPO2) ≤93% or arterial oxygen partial pressure (PaO2)/ fraction of inspired O2 (FiO2) ≤300 mmHg;
- •Known allergy or hypersensitivity to Favipiravir or any of its excipients, or to placebo excipients
- •Known severe renal impairment [creatinine clearance (CrCl) <30 mL/min] or having received continuous renal replacement therapy, hemodialysis or peritoneal dialysis;
- •Possibility of the subject being transferred to a non-study hospital within 72h;
- •Pregnant or lactating women;
- •Having used Favipiravir or participated in any other interventional drug clinical study within 30 days prior to first dose of study drug or having received treatments with other Investigational Medicinal Products (IMPs) or previous therapies within two weeks or five times the half-life of the drug, whichever is longer, must lead to exclusion
- •Persons, who were placed in an institution due to official or legal orders should be excluded
- •Persons, who are dependent on the sponsor, the investigator or the trial site, meaning that the voluntary nature of their consent is no longer guaranteed, must be excluded from participation
研究组 & 干预措施
Favipiravir
Experimental
Favipiravir Tablets, 200 mg/tablet Favipiravir combined with supportive care recommended in the current National/Local guidelines. Favipiravir dosage and method of administration: Day 1: 1800mg, BID; Day 2 and thereafter: 600mg, TID, for a maximum of 14 days.
干预措施: Favipiravir (Drug)
Placebo
Placebo Comparator
Placebo control group Favipiravir combined with supportive care recommended in the current National/Local guidelines
干预措施: Placebo (Other)
结局指标
主要结局
Time from randomization to clinical recovery
时间窗: 28 days
The duration from start of treatment (Favipiravir or placebo) to normalization of pyrexia, respiratory rate and SPO2 and relief of cough (where there are relevant abnormal symptoms at enrolment) that is maintained for at least 72h. Criteria for normalization or relief: * Pyrexia (body temperature): axillary ≤37℃，or oral≤37.5℃，or rectal or tympanic ≤38℃; * Respiratory rate: ≤24/min without oxygen inhalation; * SPO2: \>94% without oxygen inhalation; * Cough: Subject-perceived improvement or resolution of cough.
次要结局
- Time from randomization to resolution of pyrexia(28 days)
- Negativity in RT-PCR nucleic acid test(28 days)
- Time from randomization to relief of cough(28 days)
- Incidence of deterioration/aggravation of pneumonia(28 days)
- Time from randomization to relief of dyspnoea(28 days)
- Rate of auxiliary oxygen therapy or non-invasive ventilation(28 days)
- ICU admission rate within 28 days of randomization(28 days)
- All-cause mortality within 28 days of randomization.(28 days)
研究者
研究点 (9)
Loading locations...
相似试验
已完成
3 期
Efficacy and Safety of Plecanatide Comparing With Placebo in the Treatment of Functional ConstipationFunctional ConstipationNCT05151328Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.648
Unknown
3 期
Efficacy and Safety Study of PEX168 in Combination Therapy Diabetes Mellitus Type 2 Patients With MetforminType 2 Diabetes MellitusNCT02477969Jiangsu Hansoh Pharmaceutical Co., Ltd.587
招募中
3 期
Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque PsoriasisPsoriasisNCT06477237Huabo Biopharm Co., Ltd.400
进行中（未招募）
3 期
A Study of the Efficacy and Safety of SHR-1314 for Adult Active Psoriatic ArthritisPsoriatic ArthritisNCT06640257Suzhou Suncadia Biopharmaceuticals Co., Ltd.208
已完成
3 期
A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of SHR-1918 in Patients With Homozygous Familial HypercholesterolemiaHomozygous Familial HypercholesterolemiaNCT06723652Beijing Suncadia Pharmaceuticals Co., Ltd55